The following information is presented for educational purposes only. Medical Marijuana Inc. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred.
Study Concludes Cannabidiol (CBD) Product RSHO-X™ Beneficial and Therapeutic Treatment for Severe Epilepsy Symptoms, Mexican Neurologist Reports 86% of Cases Experienced Reduction in Motor Seizures with Seven Patients Find Completing Relief
SAN DIEGO – March 14, 2017 – Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico is holding a press conference in Mexico City, Mexico, today to reveal the positive results of a recent study conducted by renowned Mexican physician Dr. Saul Garza Morales on the effects of the Company’s Real Scientific Hemp Oil-X™ (RSHO-X™) product in treating children with severe epilepsy.
The study, conducted by Mexican pediatric neurologist Dr. Garza, included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 7 reported a complete elimination of all seizures over a 4-month period, with zero reported side effects.
“The results of this study are very exciting as they show the best results of any product/medication ever recorded regarding the reduction of seizures in Lennox-Gastaut Syndrome patients, with 17% of patients in the study experiencing 100 percent relief from their seizures,” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “Studies that prove the therapeutic benefits of CBD are vital, as they will continue to help fuel less restrictive medical cannabis programs not only in Mexico, but across the globe. This is such encouraging news that children with such a severe form of epilepsy now have an option for relief as opposed to a prior bleak diagnosis that offered no signs of beneficial treatment, once the epilepsy moves to the refractory (drug resistant) phase.
“Dr Garza’s study is a huge victory for botanical CBD as opposed to the pharmaceutically developed alternative,” continued Dr. Titus. “We fully believe in the Entourage Effect of the natural botanical product – both in terms of safety as well as efficacy.”
In addition, the study showed twice the efficacy in seizure reduction as per GW Pharmaceuticals’ Epidiolex – with zero reports of adverse side effects. In contrast, 79% of children in GW’s Epidiolex study reported suffering adverse effects and 30% suffered severe adverse events. For more information on GW Pharmaceuticals’ study see this report.
HempMeds® Mexico’s zero-Tetrahydrocannabinol (THC) RSHO-X™ was the first-ever cannabis product to receive approval from the federal government of Mexico, COFEPRIS, for importation. RSHO-X™ is also the first cannabis-based product to qualify as safe for World Anti-Doping standards. It has become the CBD supplement of choice for Olympic athletes and those interested in avoiding THC, including first responders, like police, firefighters, and EMTs.
Results of this study are set to be published in the near future and formally presented at the International Epilepsy Congress in Barcelona, Spain, Sept. 2-6, 2017.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P: 888-829- 0070